IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Files Provisional Patent for Treatment of Eating Disorders Using Cannabis Extracts

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced its filing of a provisional patent for the treatment of multiple types of eating disorders by a method and combination of cannabis extracts and other compounds. Should this filing result in the issuance of a patent, IGC intends to develop its IGC-506 candidate for both human and veterinary use. “The development of cannabis-based combination therapies represents a large, unique opportunity, and we believe we are the first mover in this emerging specialty-pharmaceutical sector,” Ram Mukunda, chief executive officer of IGC, stated in this morning’s news release. “Over the past three years, we have built a strong IP portfolio and now propose to obtain funding to commence pre-clinical and clinical trials as appropriate. Securing FDA approval for combination therapies is generally much faster and less expensive than the process for new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner.” The company’s patent portfolio currently includes IGC-501 for the treatment of neuropathic pain, IGC-502 for the treatment of seizures and IGC-504 for eating disorders, including cachexia.

To view the full press release, visit http://nnw.fm/4BguG

About IGC

India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information visit www.igcinc.us